IgG裂解平台
搜索文档
Hansa Biopharma AB (publ) (HNSBF) Discusses Phase III Trial Data and Developments in IgG-Cleaving Platform for Kidney Transplantation and Autoimmune Diseases Transcript
Seeking Alpha· 2025-11-13 02:11
PresentationGood morning, and welcome to the Hansa Biopharma virtual KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Hansa's website following the conclusion of the event. I'd now like to turn the call over to Renee Aguiar-Lucander, Chief Executive Officer of Hansa Biopharma. Please go ahead, Renee.Renee Aguiar-LucanderChief Executive Officer Thank you very much, Tara, and welcome, everybody, and thank you for attending this webinar o ...